Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)

Organon and Co442 enrolled

Overview

The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.

The duration of treatment is 10 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

442

Conditions

Hypercholesterolemia Coronary Disease

Interventions

MK0653, ezetimibeDRUG

Comparator: ezetimibe, placeboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with elevated cholesterol and coronary heart disease Exclusion Criteria: * Patients who have cholesterol levels within normal ranges as identified by the study

Outcomes

Primary Outcomes

Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment.

Secondary Outcomes

Safety and tolerability.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.